Modafinil for POTS: Can It Help Brain Fog and Fatigue?

Living with POTS can make everyday activities unexpectedly difficult. Alongside rapid heart rate (HR), dizziness, and exercise intolerance, many people experience persistent brain fog, difficulty focusing, tiredness, and daytime drowsiness. These manifestations can interfere with work, study, social activities, and daily responsibilities, leading some patients to explore medicines that may improve alertness and mental function.

One medicine that has attracted attention is modafinil. But what does a randomized trial say about modafinil for POTS? This guide examines modafinil and POTS, why POTS can cause brain fog and fatigue, whether modafinil may help, and what research has found. It also covers HR, blood pressure, side effects, safety, traditional stimulants, Long COVID, and post-COVID dysautonomia.

What Is POTS (Postural Orthostatic Tachycardia Syndrome)?

Postural orthostatic tachycardia syndrome (POTS) is a chronic autonomic nervous system disorder that induces an outrageous increase in HR when a person stands, often accompanied by manifestations of orthostatic intolerance. In adults, diagnosis generally involves a sustained heart-rate upsurge of at least 30 beats/minute within 10 minutes of standing, without orthostatic hypotension; the threshold is generally 40 pulsations/minute for adolescents [1].

The autonomic nervous system normally helps control heart acceleration, blood vessels, blood pressure, and circulation during posture changes. In POTS, this regulation is impaired, which can contribute to blood pooling in the lower body and an exaggerated heart-rate response. The underlying mechanisms vary among patients, making POTS a heterogeneous syndrome. Common symptoms include lightheadedness, palpitations, weakness, activity intolerance, nausea, sleep problems, fatigue, difficulty concentrating, and brain fog. Ultimately, on Reddit, discussions across subreddits like r/POTS offer a wide spectrum of POTS-related brain fog and chronic fatigue, among other pointers.

Why Do People with POTS Experience Brain Fog and Fatigue?

Brain fog is a commonly reported cognitive symptom of POTS. It may involve difficulty concentrating, impaired attention, slower thinking, memory problems, difficulty processing information, word-finding problems, or feeling that the mind has gone blank. Patients may describe it as brain fog, cognitive clouding, or cognitive fatigue, with severity varying between individuals [1].

In one social-media-based questionnaire study, more than 95% of respondents with POTS reported cognitive impairment, with most experiencing symptoms daily. Importantly, brain fog is not necessarily restricted to standing and may persist while sitting or lying down, potentially interfering with work, education, communication, and daily activities [1].

Several factors may contribute, including abnormal autonomic regulation, reduced venous return, blood pooling, altered sympathetic activity, and changes in cerebral blood flow regulation. Impaired cerebral circulation during upright posture is associated with poorer cognitive performance. Sleep disruption, physical deconditioning, and overlapping conditions such as chronic fatigue syndrome may further increase the burden.

Fatigue is broader than brain fog. Physical fatigue may involve reduced stamina or exhaustion after ordinary activity, while cognitive fatigue can make sustained mental effort difficult. A systematic review of 13 studies found that fatigue was severe in those with POTS. Fatigue affected multiple domains, while brain fog was identified as an important POTS symptom that could negatively affect productivity and cognition [2].

Can Modafinil Help with POTS?

Modafinil for POTS remains an investigational rather than an established, approved treatment. The interest is understandable: POTS can involve disabling brain fog, reduced alertness, fatigue, and difficulty maintaining normal daytime function, while modafinil is a wakefulness-fostering medicine that can increase alertness. Its potential role has therefore been considered, particularly when cognitive symptoms or excessive daytime sleepiness (EDS) are prominent. However, improving wakefulness is not the same as correcting the autonomic dysfunction that causes POTS.

Modafinil for POTS Brain Fog

POTS can cause substantial brain fog, including difficulty concentrating, slowed thinking, forgetfulness, and problems sustaining mental effort. Because modafinil promotes wakefulness and affects neurotransmitter systems involved in alertness and attention, it has been considered an off-label option for cognitive symptoms associated with POTS.

The potential benefit is primarily theoretical. Modafinil affects dopamine, norepinephrine, histamine, and other signaling systems involved in wakefulness, attention, and cognitive function. These effects could potentially improve alertness, concentration, and mental performance, but they do not establish that modafinil corrects the underlying causes of POTS-related brain fog.

Importantly, there is insufficient clinical evidence to show that modafinil reliably improves brain fog or objective cognitive performance specifically in people with POTS. Although its wakefulness-fostering effects provide a rationale for investigation, this does not mean the medication is clinically proven to resolve the cognitive difficulties associated with the syndrome.

Modafinil for POTS Fatigue

Fatigue is common and can be one of the most disabling features of POTS. Importantly, however, fatigue is not the same as EDS. Fatigue can mean physical exhaustion, reduced stamina, or mental tiredness without an increased tendency to fall asleep; EDS specifically refers to difficulty staying awake during normal daytime activities. A systematic review of orthostatic disorders found that fatigue was particularly severe in POTS and involved multiple dimensions, while brain fog was also an important contributor to impaired daily functioning [2].

This distinction matters when considering modafinil. The medicine promotes wakefulness due to daytime sleepiness and reduces alertness rather than the underlying physical fatigue caused by POTS. Becoming more awake does not necessarily mean having greater exercise tolerance, less postural exhaustion, or improved recovery after activity. The evidence-based conclusion is therefore narrow: modafinil may theoretically help a person with POTS who has significant daytime sleepiness or reduced alertness, but there is currently insufficient direct evidence that it improves POTS-related fatigue.

What Does the Research Say?

The evidence comes from a randomized, placebo-controlled crossover test involving 54 patients with POTS [3]. Participants received 100 mg of modafinil or a placebo. Researchers measured seated and standing HR and systolic blood pressure before treatment and hourly for four hours. The study examined whether modafinil’s sympathetic effects could worsen POTS tachycardia or orthostatic symptoms.

Heart rate findings were reassuring. Over four hours, standing HR was not dissimilar between modafinil and placebo (P=0.328). POTS symptom scores were identical: 14±12 with modafinil versus 14±12 with placebo (P=0.962). However, modafinil increased blood pressure. At four hours, seated systolic blood pressure averaged 109 mmHg with modafinil versus 104 mmHg with placebo (P=0.004), with significant increases in seated and standing systolic blood pressure over time.

The study had limitations: it was small, assessed acute effects, used a single 100-mg dose, and did not evaluate fatigue, brain fog, quality of life, or functional capacity. Its cardiovascular and symptom findings cannot prove that modafinil treats POTS cognitive impairment.

Does Modafinil Affect Heart Rate in People with POTS?

Because excessive standing HR defines POTS, whether modafinil could worsen tachycardia is an important safety question. Modafinil has sympathomimetic-like cardiovascular effects, prompting researchers to examine whether it further increases HR in people with POTS. The most direct evidence comes from a randomized, placebo-controlled crossover trial involving 54 patients with POTS.

Participants received a single 100-mg dose of modafinil or placebo on separate study days. Moreover, seated and standing HRs were calculated hourly for 4 hours. Standing HR declined over the observation period in both groups, and the difference was not statistically significant. At four hours, standing HR was 105 ± 16 beats/minute with modafinil versus 101 ± 16 with placebo (P = 0.139). The change in orthostatic HR was not extremely distinct between treatments.

These findings suggest that a single 100-mg dose did not significantly worsen standing tachycardia at the group level during four hours. However, this does not prove modafinil cannot increase HR in an individual. The study was small, acute, predominantly female, and did not assess long-term treatment. Separate research in 12 healthy normal subjects using a 400 mg dose found that modafinil greatly boosted resting HR by an average of 9.2 ± 2.0 beats/minute ($P=0.001$), demonstrating that modafinil directly alters autonomic regulation of HR under specific conditions [4].

Modafinil and Blood Pressure

Blood pressure produced a clearer signal in the POTS trial than HR did. Although the researchers were primarily concerned that modafinil might aggravate tachycardia, the 100 mg dose significantly increased systolic blood pressure compared with placebo during the four-hour observation period. The effect was seen in both seated and standing measurements. At four hours, seated systolic blood pressure was 109 ± 12 mmHg with modafinil compared with 104 ± 10 mmHg with placebo (P = 0.004). Standing systolic blood pressure also increased significantly over time with modafinil.

Importantly, the treatment did not significantly change the orthostatic increase in systolic blood pressure. In other words, modafinil raised overall blood pressure but did not significantly change the difference in systolic pressure between sitting and standing. The investigators considered the observed increase modest and not clinically significant in the context of their study.

Nevertheless, blood pressure deserves attention when considering modafinil for POTS because patients can have different hemodynamic profiles. A medication that raises blood pressure may have different implications depending on whether a patient’s main problem involves low blood pressure, normal pressure, or hypertension. Official prescribing information also recommends appropriate monitoring of blood pressure and heart rate and advises caution in people with cardiovascular disease [5].

Can Modafinil Make POTS Symptoms Worse?

Modafinil can potentially exacerbate certain symptoms, though trial data shows mixed findings regarding overall impact:

• trial evidence: In a randomized crossover trial of 54 POTS patients, a single 100 mg dose did not significantly increase acute orthostatic symptom burden compared to placebo (4-hour symptom scores: 14 ± 12 vs. 14 ± 12; P = 0.962). Scores for mental clouding were also virtually identical;
• general side effect profile: Standard prescribing information notes side effects like palpitations, tachycardia, anxiety, dizziness, insomnia, headache, and elevated blood pressure—all of which overlap with core POTS symptoms;
• cardiovascular strain: A 400 mg dose study in healthy adults showed modafinil significantly increased resting heart rate, confirming its capacity to stimulate central sympathetic outflow [4];
• individual variability: Group trial results on single-dose tolerability do not guarantee long-term safety for every individual. Patients experiencing worsening cardiovascular symptoms, severe palpitations, or elevated blood pressure require individual medical evaluation.

Individual responses can differ, so new or substantially worsening side effects should be medically assessed rather than assumed to be part of the expected POTS pattern.

Potential Benefits of Modafinil for POTS

Modafinil’s potential role in POTS targets daytime wakefulness and general alertness rather than correcting the underlying autonomic dysfunction. In patients where POTS is accompanied by EDS, reduced concentration, unrefreshing sleep, or mental fog, a wakefulness-promoting agent may theoretically help sustain the vigilance needed for work, study, or daily tasks. While cognitive benefits observed in non-POTS populations offer a rationale for considering modafinil, these findings cannot be assumed to transfer directly to POTS-related cognitive deficits.

Crucially, these potential advantages remain theoretical rather than proven clinical outcomes. In a randomized crossover trial, a single 100 mg dose of modafinil failed to yield significant improvements in overall symptom burden or specific mental-clouding scores [3]. Furthermore, the trial was not designed to assess long-term impacts on fatigue, objective cognitive performance, or quality of life. Consequently, modafinil should not be presented as a proven treatment for POTS brain fog, physical fatigue, or dysautonomia, and any potential wakefulness benefits must be carefully weighed against individual cardiovascular risks.

Possible Side Effects and Safety Considerations

Modafinil is a prescription medicine, not a harmless “energy booster,” and can cause adverse effects and drug interactions. Reported side effects include headache, nausea, nervousness, anxiety, dizziness, insomnia, reduced appetite, chest pain, hypertension, palpitations, and tachycardia. For people with POTS, particular attention is given to cardiovascular symptoms, including increased heart rate, palpitations, and blood pressure changes. Anxiety, nervousness, or overstimulation may also intensify existing symptoms, while insomnia can worsen daytime fatigue and cognitive difficulties.

Official prescribing information also warns about rare but serious reactions, including severe skin reactions, angioedema, anaphylaxis, multi-organ hypersensitivity, psychiatric symptoms, and cardiovascular events. Seek prompt medical attention for chest pain, fainting, severe palpitations, severe rash, swelling, breathing difficulty, or significant psychiatric changes. Anyone considering modafinil for POTS should discuss its potential benefits, risks, interactions, and monitoring needs with a clinician familiar with their cardiovascular and autonomic health.

Modafinil for POTS vs Traditional Stimulants

Modafinil is sometimes grouped with stimulants because it promotes wakefulness, but it is pharmacologically different from conventional psychostimulants such as amphetamine and methylphenidate. This distinction matters when a person with POTS has difficulty staying awake or maintaining alertness during the day. Modafinil’s potential role in POTS is more about wakefulness and alertness than correcting the autonomic dysfunction underlying the syndrome. Traditional stimulants have also been investigated in POTS, with positive impact, but the available evidence remains limited.

A systematic review identified several pharmacological approaches, including modafinil and stimulant-type medicines, while emphasizing the need for larger, better-designed trials [6]. There is currently no robust head-to-head evidence showing that modafinil is safer or more effective than conventional stimulants specifically for POTS. Treatment, therefore, needs to be individualized based on the patient’s symptoms, cardiovascular profile, other medications, and clinical diagnosis.

Modafinil for POTS and Long COVID

Long COVID can involve neurological and autonomic problems, including brain fog, fatigue, dysautonomia, and POTS. After SARS-CoV-2 infection, some people develop POTS as part of post-acute sequelae of COVID-19 (PASC), while others experience broader autonomic dysfunction without meeting formal POTS criteria. Brain fog and fatigue are also commonly reported, and proposed mechanisms include immune dysregulation, inflammation, autoantibodies, microvascular dysfunction, altered renin-angiotensin signaling, and other biological changes [7].

A systematic review identified 21 reports involving 68 people with post-COVID POTS. Palpitations, chest pain, lightheadedness, and debilitating fatigue were common, with symptoms often persisting for months, although many patients improved over time [8]. More recent research continues to identify POTS, cognitive dysfunction, and fatigue as important features of Long COVID [9]. However, there is no direct clinical evidence that modafinil treats Long COVID-associated POTS or post-COVID brain fog. The randomized modafinil trial in POTS was conducted in a general POTS population, not specifically in patients with Long COVID.

The Verdict: Does Modafinil Help POTS Brain Fog and Fatigue?

Modafinil has been studied in POTS, but current evidence is insufficient to establish it as an effective treatment for POTS-related brain fog or fatigue. In the available trial, 100 mg of modafinil did not significantly increase standing heart rate or worsen overall acute POTS symptoms compared with placebo, while systolic blood pressure increased. These findings suggest that some patients may tolerate modafinil without an immediate worsening of orthostatic tachycardia. However, the study does not show that modafinil improves the cognitive or fatigue-related symptoms of POTS.

Because individual responses can vary, particularly in people with cardiovascular or blood-pressure concerns, individualized medical assessment is required before using modafinil. A qualified clinician can help determine whether its potential benefits for alertness outweigh the risks for a particular patient.

Frequently Asked Questions

Does modafinil help POTS?

Modafinil may help some symptoms such as EDS or reduced alertness, but current evidence is insufficient to show that it effectively treats POTS itself.

Can modafinil help with POTS brain fog?

There is no strong clinical evidence that modafinil specifically improves POTS-related brain fog. Any benefit may be linked to increased wakefulness rather than correction of the underlying cognitive mechanisms.

Does modafinil help POTS fatigue?

Evidence specifically supporting modafinil for POTS fatigue is limited. It may improve wakefulness when sleepiness is contributing to daytime impairment, but fatigue and excessive daytime sleepiness are not the same symptom.

Does modafinil increase heart rate?

Yes, modafinil can augment HR in some individuals and may induce tachycardia or palpitations. However, in the randomized POTS trial, a single 100 mg dose did not produce a statistically significant increase in standing heart rate compared with placebo during four hours of monitoring. This does not mean an individual with POTS cannot experience an increase in heart rate while taking modafinil.

Can modafinil make POTS worse?

Potentially. Modafinil can cause dizziness, anxiety, insomnia, palpitations, tachycardia, and increased blood pressure, which may aggravate manifestations in some individuals with POTS. However, the randomized POTS trial did not find a significant worsening of overall acute POTS symptom burden with a 100 mg dose compared with placebo.

Is modafinil approved for POTS?

Modafinil is not FDA-approved to treat POTS. Instead, it’s approved specifically to manage extreme daytime drowsiness induced by conditions like obstructive sleep apnea, narcolepsy, and shift work sleep disorder. While some physicians may occasionally prescribe it off-label to combat chronic fatigue or other health conditions, it’s not a standard or officially indicated treatment for the condition.

Can modafinil be used for dysautonomia?

Modafinil has been studied specifically in people with POTS and may sometimes be considered off-label for symptoms such as EDS or reduced alertness. However, it is not an established treatment for dysautonomia itself, and evidence does not currently support its routine use across dysautonomia disorders. Its potential role depends on the specific autonomic condition, symptoms, cardiovascular status, and clinical judgment.

References

1. Cognitive and Psychological Issues in Postural Tachycardia Syndrome. By Vidya Raj, Morwenna Opie, and Amy C. Arnold. Published: December 1, 2019. Pmc.ncbi.nlm.nih.gov.
2. Faintly tired: a systematic review of fatigue in patients with orthostatic syncope. By Ryan E. Y. Wu, Farhaan M. Khan, Brooke C. D. Hockin, et al. Published: June 10, 2022. Pubmed.ncbi.nlm.nih.gov.
3. Hemodynamic Profiles and Tolerability of Modafinil in the Treatment of POTS: a randomized placebo-controlled trial. By Alvin G Kpaeyeh, Philip L Mar, Vidya Raj, et al. Published: December 1, 2025. Pmc.ncbi.nlm.nih.gov.
4. Modafinil elicits sympathomedullary activation. By Indu Taneja, Andre Diedrich, Bonnie K. Black, Daniel W. Byrne, Sachin Y. Paranjape, and David Robertson. Published: April 2005. Pubmed.ncbi.nlm.nih.gov.
5. Modafinil: Package Insert / Prescribing Info. Medically reviewed by Drugs.com. Retrieved: September 17, 2026. Drugs.com.
6. Choices and Challenges With Drug Therapy in Postural Orthostatic Tachycardia Syndrome: A Systematic Review. By Advait M. Vasavada, Deepak Verma, Vineetha Sheggari, et al. Published: May 2023. Pubmed.ncbi.nlm.nih.gov.
7. Current concepts in long COVID-19 brain fog and postural orthostatic tachycardia syndrome. By Jinny Tavee. Published: November 2024. Pubmed.ncbi.nlm.nih.gov.
8. Postural Orthostatic Tachycardia Syndrome After COVID-19: A Systematic Review of Therapeutic Interventions. By Gerardina Abbate, Beatrice De Iulio, Georgia Thomas, et al. Published: July 2023. Pubmed.ncbi.nlm.nih.gov.
9. Current update on the neurological manifestations of long COVID: more questions than answers. By Maria-Ioanna Stefanou, Evangelos Panagiotopoulos, Lina Palaiodimou, et al. Published: November 2024. Pubmed.ncbi.nlm.nih.gov.